Kratom (Mitragyna Speciosa): Dependence, Withdrawal, and Recovery Support

Kratom is sold as a plant, a tea, and a legal alternative to opioids, and none of those labels tell you what it does in the body. Its two main alkaloids, mitragynine and 7-hydroxymitragynine, activate the same mu-opioid receptors that oxycodone and heroin do (NIDA). That is why regular use can lead to tolerance, dependence, and a withdrawal that feels a lot like coming off an opioid. The FDA has not approved kratom for any use and warns against taking it at all (FDA). This page covers how use turns into a problem, what withdrawal looks like, what treatment involves, and how ongoing support at home fits in.

What kratom is and how it works

Kratom is the common name for Mitragyna speciosa, a tree native to Southeast Asia, and for the products made from its leaves. In the United States it is sold as powder, capsules, liquid extracts and "shots," and brewed as tea (NIDA). Street and regional names include biak, ketum, kakuam, thang, and thom (DEA). Retail brands like OPMS, MIT45, and Krave are sold in smoke shops, gas stations, and online.

The effects depend on the dose. People report that "smaller doses of kratom produce stimulant-like effects and larger doses produce opioid- or sedative-like effects" (NIDA). The opioid side comes from mitragynine, which the body also converts into 7-hydroxymitragynine (7-OH), a compound the FDA describes as having "substantially greater mu-opioid receptor potency" than mitragynine or morphine (FDA).

Legally, kratom sits in a strange spot. It is not a federally controlled substance; the DEA lists it as a "drug of concern," and NIDA notes that kratom products "are currently legal and accessible online and in stores in many areas of the United States" (NIDA). At the same time, the FDA says kratom "is not lawfully marketed in the U.S. as a drug product, a dietary supplement, or a food additive" and warns consumers not to use it "because of the risk of serious adverse events, including liver toxicity, seizures, and substance use disorder" (FDA).

One distinction matters. In July 2025 the FDA recommended scheduling 7-OH under the Controlled Substances Act, and was specific that the action targeted "7-OH, a concentrated byproduct of the kratom plant; it is not focused on natural kratom leaf products" (FDA, July 2025). In July 2026 the DEA began the process to temporarily place concentrated 7-OH in Schedule I (FDA). Those tablets are a different product with a different risk profile, and we cover them on a separate page.

Why people use kratom and how it turns

Almost nobody we work with picked up kratom to get high. An estimated 1.7 million Americans aged 12 and older used it in 2021 (FDA), and the reasons we hear are practical. Chronic pain after a doctor stopped writing opioid prescriptions. Anxiety that nothing else touched. Fatigue at a physical job. And, very often, opioid withdrawal: someone trying to get off heroin, fentanyl, or pills on their own reads that kratom takes the edge off, and it does, because it works the same receptors. The first published case series on treating kratom dependence with buprenorphine described two patients "using kratom to self-treat chronic pain after prescription opioids were discontinued" (Buresh, 2018).

The turn is gradual and easy to miss. A few grams in the morning becomes a few grams three times a day because the energy wears off sooner. Then a dose before bed because sleep is bad without it. Then the first morning without it, when the aches and sweats show up and the person realizes they are taking kratom to avoid feeling sick. The FDA's summary of the case reports it has reviewed covers the same ground: tolerance, cravings, withdrawal when use stopped, and continued use "despite adverse consequences" (FDA). Because it is legal and sold next to energy drinks, people take longer to name the pattern.

Signs kratom has become a problem

These are the things members and families describe most. Doses that have climbed steadily, often measured in scoops or capsules an hour rather than a day. Withdrawal on any morning the supply runs out: runny nose, yawning, muscle aches, sweating, diarrhea, anxiety, and restlessness. Constipation, weight loss, and poor appetite, which the DEA lists among the effects of long-term use (DEA). Hiding the amount from a partner, or waving it off as "just a plant." And, for people who came from opioids, drifting back to the original drug when kratom no longer holds the withdrawal off.

One medical note. Case reports link "regular, long-term, kratom use in large amounts" to serious liver problems (NIDA), so yellowing skin or eyes, dark urine, or a seizure in a heavy user needs a doctor the same day.

Is stopping kratom dangerous?

Kratom withdrawal is unpleasant and sometimes severe, but it is not usually life-threatening the way alcohol or benzodiazepine withdrawal can be. NIDA's summary is that "people may experience mild to moderate withdrawal symptoms when they stop regular kratom use" (NIDA), and the New York State Department of Health describes the symptoms as "similar to those experienced with opioids" (NY State Department of Health). In our experience the intensity tracks the dose. A few cups of tea a day means a rough week. Extract shots around the clock can look like coming off a serious opioid habit.

The real danger is what happens after. People who stop kratom and feel terrible tend to go back to whatever works fastest, and for many that is the opioid they were using before, at a tolerance that has dropped and from a street supply dominated by fentanyl. If someone in your house is quitting kratom and has any opioid history, keep naloxone on hand. Two other cautions. Do not stop alcohol or benzodiazepines cold at the same time; those withdrawals are the dangerous ones and need medical advice. And if you are pregnant, talk to a doctor before stopping, since the FDA has documented neonatal abstinence syndrome in newborns exposed to kratom (FDA).

Kratom withdrawal timeline

The timing depends on how much, how often, which products, and what else is in the mix. Mitragynine has a terminal half-life of about one day in regular users (Trakulsrichai et al., Drug Des Devel Ther, 2015), though people who dose several times a day feel the drop sooner. This is the general shape.

First 12 to 24 hours

Early symptoms look like a bad cold with a side of anxiety: yawning, runny nose, watery eyes, sweating, irritability, and cravings.

Days 1 to 3

Symptoms usually peak here. Muscle and bone aches, stomach cramps, diarrhea, chills, restless legs, insomnia, and a low, agitated mood are the common complaints. This is where most people relapse, because one dose makes all of it stop within the hour.

Days 4 to 7

The physical symptoms ease for most people. Sleep is still poor and energy is low. Cravings are strongest around the old routine: the morning scoop, the afternoon slump, the drive past the smoke shop.

Weeks 2 to 4 and beyond

Low mood, fatigue, anxiety, and disrupted sleep can linger, especially for people who were using kratom to manage pain or anxiety in the first place. Those original problems come back uncovered, and planning for that ahead of time is most of the work.

How treatment for kratom dependence works

There is no FDA-approved medication for kratom withdrawal or kratom use disorder. NIDA states that "there are currently no approved medical therapies" and that only "in very limited cases" have researchers reported using medications for it (NIDA). In practice, clinicians borrow from opioid care.

Tapering is the usual first step: cutting the dose gradually, under a clinician's guidance, rather than stopping outright. The New York State Department of Health tells clinicians that helping patients through kratom withdrawal "may include tapering, use of alpha-2 agonists such as clonidine and possibly medications for opioid use disorder particularly for those with a history of opioid use disorder" (NY State Department of Health). Clonidine eases the sweating, cramps, and agitation without being an opioid.

Buprenorphine is the medication with the most published support. In the 2018 case series, both patients "were successfully transitioned to buprenorphine-naloxone maintenance via home initiation with control of both their opioid withdrawal and chronic pain" (Buresh, 2018). Two patients is not a trial. But for someone who came to kratom from opioids, or who has a heavy extract habit, a buprenorphine prescriber is worth a conversation, and that decision belongs to a doctor.

Whatever the medical plan, the other half is treating what the kratom was covering. A plan that stops the kratom and ignores the pain, anxiety, or opioid use disorder underneath it will not hold.

Kratom with alcohol, opioids, and other drugs

Most of the serious harm reported with kratom involves something else in the mix. NIDA notes that "case reports suggest using kratom in combination with other drugs (sometimes called polysubstance use) may produce severe adverse effects, such as liver problems or even death," and that a 2019 report found 11 deaths between 2011 and 2017 associated with kratom exposure, only two with kratom alone (NIDA). The FDA warns that kratom's compounds can produce "respiratory depression that may lead to death" (FDA). Add alcohol, benzodiazepines, or an actual opioid, and the sedation stacks. The New York guidance is to avoid mixing kratom with "depressants including alcohol, opioids, benzodiazepines and dissociatives" (NY State Department of Health).

Contamination is the other risk. In 2018 the CDC investigated a multistate Salmonella outbreak linked to kratom products: 199 people infected across 41 states, 50 of them hospitalized, and investigators never found a single source (CDC). The FDA has also warned about kratom products with "concerning levels of heavy metals" (FDA). There is no manufacturing standard and no label you can trust.

Drug testing for kratom

Kratom does not show up on standard drug panels. The tests most employers and courts use look for opiates like morphine and codeine, and mitragynine is a different molecule. The New York State Department of Health puts it simply: kratom and 7-OH "are not detected on routine drug screens though they can be ordered" (NY State Department of Health). Specialized mitragynine tests exist for urine, blood, and oral fluid, and anyone who wants to see kratom use has to ask for them. Given a half-life of about a day (Trakulsrichai et al., 2015), heavy regular use is generally detectable for several days after the last dose.

Our members use saliva-based toxicology screening that is assigned at random through the week. You do not choose whether you test; you choose who sees the results. Because kratom needs its own assay, the first thing we do with a member whose concern is kratom is make sure the screening covers it. We explain the details in our guide to how sobriety monitoring works.

How recovery from kratom works with Accountable

We are not a detox and we do not prescribe. What we provide is the long stretch after the first week, at home, for as long as you want it. It usually runs in three stages.

1. Get the full picture

In the first sessions your coach maps what is actually going on: which products, how much, how often, what the kratom was doing for you, and what happened the last time you tried to stop. We ask directly about opioids, alcohol, and benzodiazepines, because the answer changes the plan. If pain, anxiety, or an opioid history is underneath the kratom and nobody is treating it, we help you find a prescriber and, with your permission, coordinate with them.

2. Build a plan that fits your life

Kratom habits are built into daily routines: the morning scoop, the drive to the shop, the shot before a shift. Your coach helps you rebuild those routines one at a time and plan for the hard moments, like the 3 p.m. crash in week one or the flare of pain that used to send you to the cabinet. Daily peer group meetings and a weekly family Zoom group give you and your family somewhere to take it besides each other.

3. Weekly check-ins through the long stretch

The dangerous window with kratom is the second and third month, when the withdrawal is a memory and the pain or anxiety is back. Your coach shows up every week, and the random saliva screening, set up to include kratom, turns "I think he's doing okay" into a shared record you control. When a slip happens, we treat it as information. The plan changes and the support goes up. Every coach at Accountable has their own recovery behind them.

Accountable is covered by a growing list of commercial health plans, with more added each month, and private-pay plans start at $375 per month. You can check your coverage in a few minutes or call the care team at (646) 450-7641. Families are welcome to make the first call; see our page for families.

Common questions

Is kratom dependence real?

Yes. Kratom's main compounds act on mu-opioid receptors, and regular use produces tolerance and withdrawal (NIDA). The DEA lists psychological and physiological dependence among its effects (DEA). "It's just a plant" does not change the pharmacology.

Is kratom withdrawal dangerous?

Rarely on its own. It is usually described as mild to moderate and similar to opioid withdrawal (NIDA). The bigger risks are relapse to opioids afterward and stopping alcohol or benzodiazepines at the same time, which does need medical supervision.

How long does kratom withdrawal last?

For most people the worst of it is the first three days, with physical symptoms fading over about a week. Sleep, mood, and cravings can take several weeks to settle, longer if pain or anxiety was the reason for using.

Does kratom show up on a drug test?

Not on a standard panel. Mitragynine needs its own test, which can be ordered from most labs (NY State Department of Health). Our screening can include it when kratom is the concern.

Do I have to stop using kratom before I start with Accountable?

No. Many members start while they are still using or in the middle of a taper. The first job is to get an honest picture and a plan; the screening and the weekly sessions build from there.

Sources

• National Institute on Drug Abuse. Kratom. Research topic page, updated March 2026.

• U.S. Food and Drug Administration. FDA and Kratom. Public health focus page, updated December 2025.

• U.S. Food and Drug Administration. FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers. Press announcement, July 29, 2025.

• U.S. Food and Drug Administration. Hiding in Plain Sight: 7-OH Products. Public health focus page, updated July 2026.

• Drug Enforcement Administration. Kratom drug fact sheet.

• New York State Department of Health. Kratom: What Clinicians Need to Know. Revised December 2025.

• Buresh M. Treatment of Kratom Dependence With Buprenorphine-Naloxone Maintenance. Journal of Addiction Medicine. 2018;12(6):481-483.

• Trakulsrichai S, Sathirakul K, Auparakkitanon S, et al. Pharmacokinetics of mitragynine in man. Drug Design, Development and Therapy. 2015;9:2421-2429.

• Centers for Disease Control and Prevention. Multistate Outbreak of Salmonella Infections Linked to Kratom Products (Final Update). May 24, 2018.